Aptorum Group Limited

APM Details

Aptorum Group Limited (NASDAQ: APM) is a clinical-stage biopharmaceutical business focused on developing and commercializing therapeutic assets to treat disorders with unmet medical needs, notably in cancer (including orphan oncology indications) and other infectious diseases. The company's sole source of income was the provision of healthcare services in Hong Kong. As of October 25, 2021, APM's market capitalization stood at USD 88.35 million.

Latest News:

• Receipt of FDA Approval: On September 15, 2021, APM reported that the US Food and Drug Administration (FDA) approved its Investigational New Drug (IND) application to begin clinical studies of SACT-1, a repurposed minor molecule medication for the treatment of neuroblastoma that is taken orally.

H1FY21 Results:

• Rise in Sales: The company reported an increase of 94.88% in revenues to USD 0.64 million in H1FY21 (ended June 30, 2021) compared to USD 0.33 million in H1FY20 due to a rise in the number of patients being treated during the period.
• Significant Increase in Losses: Due to losses on marketable securities investments, APM's net loss increased to USD 17.10 million in H1FY21 compared to USD 6.99 million in H1FY20.
• Decent Balance Sheet: As of June 30, 2021, the company had a cash balance (including marketable securities) of USD 20.64 million with total debt (including finance lease liabilities) of USD 1.31 million.

Key Risks:

• Commercialization Risk: There are currently no authorized items for commercial distribution by the firm. Many of the company's products are still in the R&D stage and are vulnerable to failure. Furthermore, if regulatory authorities reject any medication candidate for commercialization, the company's operational and financial situation may be severely harmed.

Outlook:

• APM anticipates being able to meet its operational and capital expenditure requirements for at least the next 12 months using existing cash and restricted funds, as well as an undrawn line of credit facility from related parties.

Valuation Methodology: EV/Sales Multiple Based Relative Valuation

(Analysis by Kalkine Group)

* % Premium/(Discount) is based on our assessment of the company's NTM trading multiple after considering its key growth drivers, economic moat, stock's historical trading multiples versus peer average/median, and investment risks.

APM Daily Technical Chart (Source: REFINITIV)

Stock Recommendation:

APM stock price has fallen 27.86% in the past nine months and is trading close to the lower end of the 52-week range of USD 2.00 to USD 4.94. The stock is currently trading below its 50 and 200 DMA levels, and its RSI Index is at 40.76. We have valued the stock using the EV/Sales-based relative valuation methodology and arrived at a target price of USD 2.00.

Considering the company's uncertain growth prospects, doubtful revenue-generating capabilities, increase in losses, current valuation, and associated risks, we recommend a "Sell" rating on the stock at the closing price of USD 2.46, down 0.81% as of October 25, 2021.

* The reference data in this report has been partly sourced from REFINITIV.

* All forecasted figures and industry information have been taken from REFINITIV.

Disclaimer - This report has been issued by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and prepared by Kalkine and its related bodies corporate authorised to provide general financial product advice. Kalkine.com.au and associated pages are published by Kalkine.

Any advice provided in this report is general advice only and does not take into account your objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Statement or other offer document for the securities or other financial products referred to in Kalkine reports. You should obtain a copy of the relevant Product Disclosure Statement, Information Statement or offer document and consider the statement or document before making any decision about whether to acquire the security or product.

You should also seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice in this report or on the Kalkine website. Not all investments are appropriate for all people.

The information in this report and on the Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of information contained in its reports, newsletters and websites. All information represents our views at the date of publication and may change without notice.

Kalkine does not guarantee the performance of, or returns on, any investment. To the extent permitted by law, Kalkine excludes all liability for any loss or damage arising from the use of this report, the Kalkine website and any information published on the Kalkine website (including any indirect or consequential loss, any data loss or data corruption). If the law prohibits this exclusion, Kalkine hereby limits its liability, to the extent permitted by law, to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

On the date of publishing this report (referred to on the Kalkine website), employees and/or associates of Kalkine and its related entities do not hold interests in any of the securities or other financial products covered on the Kalkine website.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.